Industry Abstract Previews - ACR2020

Save

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.

Infection and Rheumatic Diseases: A New Dawn

Save

Infection in the setting of autoimmune rheumatic disease (ARD) has been the subject of increasing research and clinical interest for decades. Despite the huge burden of infection in patients with ARDs, this area of research has really been catapulted to the centre-stage of research agendas and coverage at congresses, including ACR 2020, with the arrival of the coronavirus disease 2019 (COVID-19) pandemic.

QD Clinic Podcast - 106 thru 109

Save

Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.

In this compilation from the past week we talk about

- HIV and arthritis

- Hyperuricemia in PsA

- An odd kind of dermatomyositis

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

Save

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

ACR 2020 Your Way - Get Your Topic Emails

Save

ACR is but a few days away; the question is: how will you tackle this virtual meeting? RheumNow has created several options for learning the way you want to. First is to feed your need. Are you a lupologist? A gout maven? A Spondylitis sleuth? A drug safety wannabe?

US Differs from Worldwide Drug Reimbursements

Save

"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine.  US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretai

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Save

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Vedolizumab Promising in Immune-Related GI Events

Save

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Telemedicine Outcomes in RA Care

Save

A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).